)
Visual21 Nov 2025
Data center suppliers
Connect Biopharma Holdings (CNTB) investor relations material
Connect Biopharma Holdings Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Advancing rademikibart, a next-generation antibody for asthma and COPD, with ongoing Phase 2 trials and positive data presented at ERS 2025 showing significant improvement in lung function and asthma control, especially in patients with elevated inflammatory markers.
Recruitment ongoing for Phase 2 Seabreeze STAT studies in acute asthma and COPD, with topline data expected in the first half of 2026.
NDA for rademikibart in atopic dermatitis accepted by China's NMPA; Simcere progressing Phase 3 asthma study.
Terminated ADR program in September 2025, with shares now directly listed on Nasdaq to enhance visibility and investor base.
Cash, cash equivalents, and short-term investments totaled $54.8 million as of September 30, 2025, expected to fund operations into 2027.
Financial highlights
License and collaboration revenue was $16,000 for Q3 2025 and $64,000 for the nine months, down from $1.2 million and $25.3 million in the prior year, reflecting the timing of milestone payments under the Simcere agreement.
Research and development expenses increased to $11.1 million for Q3 2025 and $26.5 million for the nine months, up from $9.0 million and $23.0 million, primarily due to rademikibart development costs and initiation of Phase 2 Seabreeze STAT studies.
General and administrative expenses rose to $6.6 million for Q3 2025 and $16.1 million for the nine months, compared to $6.1 million and $15.1 million, mainly due to higher professional fees.
Net loss was $17.2 million ($0.31 per share) for Q3 2025 and $40.4 million ($0.73 per share) for the nine months, compared to $12.9 million ($0.23 per share) and $6.7 million ($0.12 per share) in the prior year.
Cash and equivalents decreased from $93.7 million at year-end 2024 to $54.8 million at September 30, 2025.
Outlook and guidance
Management expects current cash resources to fund operations into 2027.
Topline data from ongoing Phase 2 acute exacerbation studies in asthma and COPD expected in the first half of 2026.
Eligible to receive up to $110 million in milestone payments and tiered royalties from Simcere for Greater China.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Connect Biopharma Holdings earnings date
Q4 202531 Mar, 2026
Next Connect Biopharma Holdings earnings date
Q4 202531 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Connect Biopharma Holdings Ltd is a global, clinical-stage biopharmaceutical company focused on developing innovative therapies for chronic inflammatory diseases by leveraging its expertise in T cell biology. The company is advancing a pipeline of novel small molecules and biologics, targeting various conditions such as atopic dermatitis, ulcerative colitis, and chronic pruritus. These therapies aim to address significant unmet medical needs by modulating immune system responses. Connect Biopharma's approach combines a deep understanding of T cell-driven research with proprietary Immune Modulation Technology Platform, aiming to significantly reduce the discovery time and cost for new, effective treatments. The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage